Memorial Sloan Kettering

October 2017 Newsletter

Issue link:

Contents of this Issue


Page 0 of 3

MSK researchers remain at the forefront in the rapidly growing field of immunotherapy. Our leadership, which began more than a century ago, recently led us to become a founding member of the Parker Institute for Cancer Immunotherapy. This new partnership will provide MSK with more resources to develop innovative new treatments for patients. Immunotherapy is a fundamentally different way of treating cancer, empowering the body's own immune system to seek out and destroy the disease. MSK research in this field has already changed the way a variety of cancers are treated. The Parker Institute involves 300 top researchers from MSK and five other founding institutions, with the goal of speeding the discovery and development of new immunotherapy treatment options to save more lives. MSK's Parker Institute members are dreaming big—pursuing projects that will not only improve existing immunotherapies but also open the door to new ones. The support offered through the Parker Institute will allow the researchers to build on MSK's leadership as we search for new ways to extend the benefits of immunotherapy to even more patients. "We are now able to act within days or weeks of having an idea for a new clinical trial to learn more, quickly," says physician-scientist Jedd Wolchok, MD, PhD, Director of the Parker Institute at MSK. About the Parker Institute The institute was established through a $250 million grant from the Parker Foundation, founded by tech entrepreneur and social network pioneer Sean Parker, known for his work with Napster and Facebook. With this partnership, immunity science at MSK now spans one academic program and four collaborative research centers. Support from friends like you helps advance MSK's research. Learn more about the promising field of immunotherapy by visiting Reflecting on the Future Fall 2017 | For Friends of Memorial Sloan Kettering Cancer Center inside: Now Is the Time | Give From Your IRA | Encouraging Clinical Trials Physician-scientists Marcel van den Brink (left) and Jedd Wolchok lead the Parker Institute for Cancer Immunotherapy at MSK. New Partnership Involving MSK Experts Puts Cancer Research on the Fast Track Power in Numbers

Articles in this issue

Links on this page

view archives of Memorial Sloan Kettering - October 2017 Newsletter